Daewoong Pharma to Test Anti-Parasite Drug for COVID-19 - COVID-19 Clinical Trial
Breaking News | COVID-19

Daewoong Pharma to Test Anti-Parasite Drug for COVID-19

South Korea’s Daewoong Pharmaceutical Co Ltd said on Tuesday it received Indian regulatory approval to test its anti-parasitic niclosamide drug to treat COVID-19 patients in an early-stage human trial.

The phase 1 trial, approved by India’s Central Drugs Standard Control Organisation (CDSCO), will involve around 30 healthy participants to test safety and kickstart this month, Daewoong said in a statement.

The South Korean drugmaker is testing the drug in partnership with New Delhi-based Mankind Pharma Ltd, which will continue the second and third phases of trials in India on mild and severe coronavirus patients.


New Zealand On Alert After 4 Cases Of COVID-19 Emerge From Unknown Source

More than three months after its last case of community spread, New Zealand has four new cases of the coronavirus from an unknown source. The island nation, seen as a global exemplar in the battle to contain the coronavirus, moved quickly to identify the source of transmission and halt further spread.

All four cases are members of the same family, who live in South Auckland, the government said Tuesday.

The first case identified in the cluster was a person in their 50s with no overseas travel history. The person has been symptomatic for five days and was confirmed positive on Tuesday. The six members of the person’s household were then tested: three tested positive and three negative.

While the cases are all in one household, more than one workplace was affected, Prime Minister Jacinda Ardern said at a late evening press conference on Tuesday in which she announced a heightened state of alert for the country.

Share this:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on reddit
Reddit
Share on email
Email
Scroll to Top

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.